Q-omics provides the consensus-scored ANO4 profile across patient tissues and cancer cell-line models. ANO4 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, ANO4 is differentially expressed in 14, with the highest sampling consensus in KIRC. Additionally, ANO4 RNA expression shows 17,920 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight UVM, KIRC, and GBM as cancer lineages where ANO4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ANO4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ANO4 survival associations across molecular data types. ANO4 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ANO4 RNA expression–survival associations across cancer types. High ANO4 expression shows unfavorable associations in UVM, STAD and LUSC, but favorable associations in KIRC, UCS and UCEC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for ANO4 RNA expression.
This table summarizes ANO4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for ANO4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ANO4 shows lower tumor expression in THCA and BLCA and higher tumor expression in KIRC, KIRP, KICH and HNSC. The KIRC box plot shows higher ANO4 RNA expression in tumor versus normal tissue (log2 FC = +1.742, t-test p < 0.001).
This table shows molecular features associated with ANO4 in patient tissues and cancer cell lines. In patient samples, ANO4 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, ANO4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in OVARY and SOFT_TISSUE.
